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Introduction
In late 2019 – early 2020, the world was hit by a pan-
demic caused by the virus causing Severe Acute Respiratory 
Syndrome (SARS-CoV-2), an infection also called 
COVID-19. This is a new coronavirus that was primarily 
reported to the World Health Organization (WHO) as a 
group of cases of viral pneumonia of unknown aetiology in 
Wuhan, China, on 31 December 2019. It is currently known 
that the cause of the disease is coronavirus (COVID-19), 
which affects both the upper and lower respiratory tract. 
On 30 January 2020, the WHO declared the outbreak of 
COVID-19 a global public health emergency. Since then, 
the infection has continued to spread around the world and 
was described by the WHO as a pandemic on 11 March 
2020.
COVID-19 virus belongs to the family of single-strand-
ed RNA viruses, some of which have been previously de-
scribed to be responsible for the Severe Acute Respiratory 
Syndrome (SARS) and Middle East Respiratory Syndrome 
(MERS). Although the symptoms and clinical presentation 
of COVID-19 are similar to SARS and MERS, the rate of 
spread is greater.
In the United Kingdom, the first cases were detected 
at the end of January 2020; the transmission among the 
population began at the end of that month. Initial reports 
from China, Italy and Spain clinically described the char-
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Abstract
Background: Review is based on the biggest observational population study of all the risk factors of COVID-19 infection. The study was carried out in 
Royal College of General Practitioners, Oxford, and covering over 4 million of people. Were studied and analyzed risk factors as: age, sex and ethnicity, 
socioeconomic level, living space dimensions, rural-urban population, body mass index, smoker status, pregnancy, hypertension, chronic kidney disease, 
ischemic heart disease, chronic respiratory diseases including asthma, and chronic obstructive pulmonary disease, and type 1 and 2 diabetes. Patient 
variable with malignancy and immunocompromised status was separated due to the small number of patients in each group.
Conclusions: By September 2020 more than 28.000 articles had been published related to COVID-19 in less than 9 months, 211 new papers every day. 
Most of them had small population of the studies. In the investigated sample, it was found that increasing age, male sex, economic deprivation, urban 
location and black ethnicity were associated with higher chances of testing positive for SARS-CoV-2. Active smoking decreased the chance of a positive 
test.  The review covers the most important subjects influencing the development of severe infection outcomes.
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acteristics of people diagnosed with COVID-19 and the 
risk factors, which include old age, male sex, pre-existing 
cardiovascular diseases, high blood pressure and diabetes. 
However, the most recent researches to date have been done 
among in-patients with COVID-19, i.e., the risk factors for 
infection in the general population have not been directly 
evaluated.
The aim of the study was to evaluate the potential risk 
factors that could influence the spread, and change the man-
agement and prevention of the spread of this new type of 
virus.
The Research and Supervision Centre of the Royal 
College of General Practitioners in Oxford includes over 
500 health centres in both urban and rural areas, covering 
over 4 million people.
Material
A cross-sectional study of patients in the Network of 
the Research and Surveillance Centre in Oxford, who were 
tested for SARS-CoV-2 between 28 January and 4 April 
2020, was performed. Pseudonymized results were taken 
from electronic primary health care records. These data 
enabled estimating the living space sizes, the isolation level 
and rural-urban classification. Starting with the last week of 
January 2020, research and surveillance centres submitted 
nasopharyngeal smears for SARS-CoV-2 testing in patients 
with symptoms of influenza or respiratory infection.
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The analytical specifics of RT-PCR assays for SARS-
CoV-2 are greater than 95% and the analytical sensitivity of 
the assays is usually 90-95%, with high performance.
 Patients registered with the research and surveillance 
centres as of 30 September 2019, and who had a record in 
their medical sheet reporting a positive or negative result 
for SARS-CoV-2 were only people with a positive test or 
negatively coded, and not those under suspicion.
Studied variables
The following independent demographic aspects were 
studied as factors: age, sex and ethnicity, using an ontology 
to maximize case identification; socioeconomic level using 
the English quintile index for multiple deprivation; living 
space dimensions based on the patient’s pseudonymized 
address; and rural-urban division. The most recent record 
of the following clinical variables was included, which are 
similar to those associated with higher susceptibility to in-
fluenza: body mass index (BMI), smoker status, pregnancy, 
hypertension, chronic kidney disease, ischemic heart dis-
ease, chronic respiratory diseases, including asthma and 
chronic obstructive pulmonary disease, and type 1 and 2 
diabetes. Patient variable with malignancy and immuno-
compromised status was created due to the small number 
of patients in each group. Malignancy was identified using 
the most recently recorded disease codes and prescriptions 
of prednisolone and antirheumatic drugs as a surrogate for 
immunosuppression with a positive test for SARS-CoV-2.
Statistical methods
Descriptive statistics and reported counts were used for 
categorical data and distribution measures for continuous 
data. Collinearity was checked by measuring the variation 
of the inflation factor for each covariate – all were consid-
ered within acceptable limits, with a maximum value below 
2.0. New sensitivity analyses were performed using only 
complete cases, non-ethnic data imputed from the census 
data.
Results
Between 28 January and 4 April 2020, 587 patients with 
positive results on SARS-CoV-2 and 3215 with negative re-
sults were obsessed with the surveillance programme. The 
first positive case reported on 30 January 2020 reaching 
the number of 100 cases on 17 March 2020. In total, 2190 
(57.6%) of 3802 patients were women and 2497 (65.7%) 
were white (tab. 1).
The data are n (%). SARS-CoV-2 = severe acute respirato-
ry syndrome – coronavirus 2.BMI = body mass index.* The 
level of socio-economic deprivation was assessed at a prac-
tical level using the English Index of Multiple Deprivation 
Quintiles. † BMI categories were based on the WHO classi-
fication (normal weight 18.5-24.9 kg/m², overweight 25.0- 
29.9 kg/m², obese 30.0-39.9 kg/m², severely obese ≥40 kg/
m²) 
In the univariate analysis, the chances of testing positive 
for SARS-CoV-2 were higher among the elderly, non-white 
men, and people living in more disadvantaged areas (tab. 
2). The chances of a positive test were lower in households 
from two to four or five to eight people. The clinical factors 
in the univariate analysis, chronic kidney diseases, obesity, 
malignancy or immunocompromise, diabetes, chronic res-
piratory diseases, chronic heart diseases, and hypertension 
were associated with higher odd ratios of a positive SARS-
CoV-2 test.
In case of active smoker, he has had a decreased level 
for a positive COVID test. In the multivariable analysis, ad-
justed for all other variables in tab. 3, male sex remained in-
dependently associated with SARS-CoV-2 positive testing. 
The age linked variable: children and people aged 40–64 
years were at a lower risk (5.36, 3.28–8.76) compared to 
adult ones and people aged 75 years and older (5.23, 3.00–
9.09) were at the highest risk. Black people were at a higher 
risk of testing positive for SARS-CoV-2 (4.75, 2.65-8.51), 
compared to white people. Were associated with higher 
odd ratios of SARS-CoV-2 test - urbanized areas (4.59, 
3.57–5.90). In the adjusted analysis, people with chronic 
kidney disease were more likely to be tested positive for 
SARS-CoV-2 than those without it (1.91, 1.31–2.78), but 
without a significant association with other chronic con-
ditions. Smoking cigarettes was associated with lower 
chances of a positive SARS-CoV-2 test result (adjusted OR 
0-49, (95% CI) 0.34-0.71). Higher odd ratios of a positive 
test among obese people was found compared to those with 
normal weight (1.41, 1.04–1.91).
 The review of the literature suggested that COVID-19 
affected men aged between 30 and 65, and about half of the 
patients were over 50 years old. There is a higher risk of a 
similar positive SARS-CoV-2 test in men as in people aged 
over 40. It is known that the chance of a positive SARS-
CoV-2 test increases with higher population density due to 
the increased social mix, which correlates with the finding 
of a high level of a positive test in urban areas. 
 Socially disadvantaged areas were found to be associ-
ated with a higher risk of other respiratory infections, and 
thus the risk of death from COVID-19 is higher in the 
poorest parts of the UK.
The decrease in the socio-economic level was associated 
with the increase of a positive test, independently of the 
area of the place of residence, urban location and smok-
ing. No association was found between household size and 
the risk of SARS-CoV-2 positivity, despite previous data 
of a higher risk of transmission through household con-
tacts. Social distancing measures could have influenced the 
transmission speed and areas. Some data raised concerns 
about the potential increased risk of complications associ-
ated with COVID-19 among black and Asian people, but 
there were few epidemiological studies that have assessed 
the risk by ethnicity. An analysis of 3370 people in the UK 
admitted to the ICU (Intensive Care Unit) with confirmed 
positive COVID-19 found that 402 (11.9%) were black, 
486 (14.4%) were Asian and 2236 (66.4%) were white [35], 
compared to the national figures that were of 3.3%, 7.5% 
and 86.0%. These results were not adjusted for socio-demo-
graphic potential or clinical confusions [36].
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Table 1.  Demographic and clinical characteristics of the study cohort [50]
SARS-CoV-2 test result Participants 3802 Pregnancy
Negative 3215 (84.6%) No 3742 (98.4%)
Positive 587 (15.4%) Yes 60 (1.6%)
Missing data 0 Missing data 0
Age
0–17 499 (13.1%) BMI†
18–39 666 (17.5%) Normal weight 1296 (34.1%)
40–64 1316 (34.6%) Overweight 1095 (28.8%)
65–74 557 (14.7%) Obesity 680 (17.9%)
≥75 764(20.1%) Morbid obesity 145 (3.8%)
Missing data 0 Missing data 586 (15.4%)
Sex
Women 2190 (57.6%) Hypertension
Men 1612 (42.4%) No 2708 (71.2%)
Missing data 0 Yes 1094 (28.8%)
Ethnicity Missing data 0
white people 2497 (65.7%)
Asian people 152 (4.0%) Chronic kidney diseases
black people 58 (1.5%) No 3595 (94.6%)
others 81 (2.1%) Yes 207 (5.4%)
Missing data 1014 (26.7%) Missing data 0
Level of socio-economic deprivation*
5 (less deprived) 1855 (48.8%) Diabetes
4 633 (16.6%) No 3299 (86.8)
3 646 (17.0%) Yes 503 (13.2)
1 and 2 (more deprived) 668 (17.6%) Missing data 0
Missing data 0
Number of people living in a common 
space
Chronic heart diseases
1 824 (21.7%) No 3202 (84.2%)
2-4 2341 (61.6%) Yes 600 (15.8%)
5-8 408 (10.7%) Missing data 0
≥9 135 (3.6%)
Missing data 94 (2.5%) Chronic respiratory diseases
Population density No 3544 (93.2%)
Rural 1986 (52.2%) Yes 258 (6.8%)
Urban 1816 (47.8%) Missing data 0
Missing data 0
Smoker status Cancers or immune compromise
Non-smoker 1125 (29.6%) No 3164 (83.2%)
Active smoker 413 (10.9%) Yes 638 (16.8%)
Ex-smoker 1753 (46.1%) Missing data 0
Missing data 511 (13.4%)
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Table 2.  univariable analysis of demographic and clinical risk factors for testing positive for SARS-CoV-2 [50]
SARS-CoV-2 positive Non-adjusted oddratio (95% Cl) p value
 <0.0001
0–17 23/499 (4.6%) 1 (ref)
18–39 84/666 (12.6%) 2.98 (1.85–4.81)
40–64 243/1316 (18.5%) 4.69 (3.00–7.28)
65–74 88/557 (15.8%) 3.88 (2.40–6.25)
≥75 149/764 (19.5%) 5.00 (3.18–7.90)
Sex <0.0001
Women 291/2190 (13.3%) 1 (ref)
Men 296/1612 (18.4%) 1.47 (1.23–1.75)
Missing data
Ethnicity
White people 388/2497 (15.5%) 1 (ref)
Asian people 47/152 (30.9%) 2.43 (1.70–3.49)
Black people 36/58 (62.1%) 8.90 (5.20–15.30)
Others 20/81 (24.7%) 1.78 (1.10–2.90)
Missing data 96/1014 (9.5%) 0.57 (0.45–0.72)
Level of socio-economic deprivation* <0.0001
5 (less deprived) 143/1855 (7.7%) 1.00 (ref)
4 112/633 (17.7%) 2.58 (1.97–3.36)
3 135/646 (20.9%) 3.16 (2.45–4.10)
1 and 2 (more deprived) 197/668 (29.5%) 5.01 (3.95–6.35)
The number of people living in a common 
space
<0.0001
1 163/824 (19.8%) 1.00 (ref)
2-4 320/2341 (13.7%) 0.64 (0.52–0.79)
5-8 53/408 (13.0%) 0.61 (0.43–0.85)
≥9 35/135 (25.9%) 1.42 (0.93–2.16)
Missing data 16/94 (17.0%) 0.83 (0.47–1.46)
Population density <0.0001
Rural 111/1986 (5.6%) 1.00 (ref)
Urban 476/1816 (26.2%) 6.00 (4.82–7.46)
Smoker status <0.0001
Non-smoker 201/1125 (17.9%) 1 (ref)
Active smoker 47/413 (11.4%) 0.59 (0.42–0.83)
Ex-smoker 303/1753 (17.3%) 0.96 (0.79–1.17)
Missing data 36/511 (7.0%) 0.35 (0.24–0.51)
Pregnancy 0.0400
No 583/3742 (15.6%) 1 (ref)
Yes 4/60 (6.7%) 0.39 (0.14–1.10)
BMI † <0.0001
Normal weight 171/1296 (13.2%) 1 (ref)
Overweight 198/1095 (18.1%) 1.45 (1.20–1.80)
Obesity 142/680 (20.9%) 1.74 (1.36–2.20)
Morbid obesity 26/145 (17.9%) 1.44 (0.91–2.27)
Missing data 50/586 (8.5%) 0.61 (0.44–0.85)
Hypertension <0.0001
No 378/2708 (14.0%) 1 (ref)
Yes 209/1094 (19.1%) 1.46 (1.20–1.75)
Chronic kidney diseases <0.0001
No 519/3595 (14.4%) 1 (ref)
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Age Non-adjusted odd ratios (95% Cl)
<0.0001




≥75   5.23(3.00–9.09)
Sex <0.0001




White people 1 (ref )
Asian people 1.46 (0.94–2.29)
Black people 4.75 (2.65–8.51)
Others 1.71 (0.97–3.01)
Missing data
Level of socio-economic 
deprivation*
5 (less deprived) 1 (ref )
4 1.51 (1.13–2.03)
3 2.35 (1.78–3.11) 
1 - 2 (more deprived) 2.03 (1.51–2.71)
The number of people living in a 
common space
0.4900






Rural 1 (ref )
Urban 4.59 (3.57–5.90)
Smoker status
Non-smoker 1 (ref )
Active smoker 0.49 (0.34–0.71) 
Ex-smoker 0.87 (0.69–1.10)
BMI † 0.0090
Normal weight 1 (ref ) 
Overweight 1.26 (0.99–1.61) 
Obesity 1.41 (1.04–1.91)
Morbid obesity 1.28 (0.78–2.10)
Missing data
Hypertension 0.3100
No 1 (ref )
Yes 0.89 (0.69–1.14)
Chronic kidney diseases
No 1 (ref ) 
Yes 1.91 (1.31–2.78)
Diabetes 0.8300
No 1 (ref ) 
Yes 1.03 (0.78–1.36)
Chronic heart diseases 0.1800
No 1(ref ) 
Yes 1.21(0.92–1.60)
Chronic respiratory diseases 0.8200






Yes 1 (ref ) 
1.01 (0.78–1.31)
Yes 68/207 (32.9%) 2.90 (2.14–3.93
Diabetes <0.0001
No 473/3299 (14.3%) 1 (ref)
Yes 114/503 (22.7%) 1.75 (1.40–2.20)
Chronic heart diseases <0.0001
No 451/3202 (14.1%) 1 (ref)
Yes 136/600 (22.7%) 1.79 (1.44–2.20)
Chronic respiratory diseases <0.0001
No 529/3544 (14.9%) 1 (ref)
Yes 58/258 (22.5%) 1.65 (1.21–2.25)
Oncological or immunocompromising 
diseases
<0.0001
No 460/3164 (14.5%) 1 (ref)
Yes 127/638 (19.9%) 1.46 (1.17–1.82)
Table 3.  Multivariable analysis of risk factors for SARS-CoV-2 positive testing [50]
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Discussion
The study has shown that black people were more likely 
to test positive for SARS-CoV-2 than white ones, which re-
mained significant even after adjusting for comorbidities, 
such as high blood pressure and diabetes, whose prevalence 
is higher in black people. Other socio-economic factors that 
we did not examine, such as high-risk professions, level of 
education, income and barriers to health care, could have 
contributed to this association and should be explored as 
soon as possible [29, 30, 32, 33].
Regular reviews showed that people with COVID-19 
who have chronic comorbidities, such as hypertension, dia-
betes and cardiovascular diseases are at high risk for severe 
COVID-19 evolution [38]. Risk factors for SARS-CoV-2 in-
fection may be different, and no evidence was found of an 
association between these conditions and a positive SARS-
CoV-2 test. It was detected that chronic kidney disease and 
obesity were associated with testing positive for SARS-
CoV-2. Both factors – chronic kidney disease and obesity 
were associated with a higher risk of other respiratory in-
fections, angiotensin-converting enzyme inhibitors, which 
are recommended as treatments for chronic kidney disease 
and were postulated to impact SARS-CoV-2 interactions on 
the host cell. However, there is no observational evidence to 
support this effect, and further analyses to investigate the 
relationship between drugs, chronic diseases, and SARS-
CoV-2 positivity would be evaluated.
Previous studies reported that smoking is associated 
with a higher risk of hospitalization in intensive care unit or 
death among people with COVID-19 [46]. Yet, several stud-
ies have reported a low prevalence of smokers among people 
with COVID-19 [47, 48]. A Chinese study found that only 
137 (12.6%) of 1085 patients with COVID-19 were current 
smokers, compared to the proportion of 27.7% of adult 
smokers in the general population, another analysis of cases 
in the Centres for Disease Control and Disease Prevention 
in the US detected that only 96 (1.3%) of 7162 COVID-19 
cases were active smokers, compared to 13.7% of smokers in 
the general US population. However, it should be admitted 
that in these studies it is sometimes difficult to identify ac-
tive smokers among patients with COVID-19.
The data obtained show that active smoking was asso-
ciated with a decrease in the chances of having a positive 
COVID-19 test result. There are several plausible reasons 
for this result. Active smoking could affect the viral load of 
the nasopharynx and therefore affect the sensitivity of the 
RT-PCR test, rather than protection against actual infection, 
although this effect is not known in the RT-PCR test for in-
fluenza. Smokers are more likely to have a cough, which 
means they may also be more likely to be tested positive 
for SARS-CoV-2 than non-smokers, even if they are SARS-
CoV-2 negative. This more frequent test could increase the 
proportion of smokers with a negative SARS-CoV-2 result 
in our sample, which would harm our results. However, the 
share of smokers in our study was low.  In addition, former 
smokers and people with chronic lung disease would also 
be expected to cough more, but these groups were not more 
likely to be tested positive for SARS-CoV-2. Therefore, the 
relationship between smoking and SARS-CoV-2 infec-
tion should be further investigated. Nicotine in turn may 
decrease the sensitivity of angiotensin-converting enzyme 
receptors, the place used by SARS-CoV-2 for entering cells, 
although studies found an increase in the concentration of 
angiotensin-converting enzyme 2 in lungs among smokers 
and people with chronic obstructive pulmonary disease. 
The findings should not be used to conclude that smoking 
prevents SARS-CoV-2 infection or to encourage continued 
smoking, especially given the well-documented damage to 
overall health caused by smoking, there may be alternative 
explanations for these findings.
Although the study group of primary care patients is 
likely to be more similar to the general population than that 
of hospital-based studies, there is a risk of bias in selection, 
as the results may reflect groups of patients who were more 
likely to come for evaluation and be selected for SARS-CoV-2 
testing in accordance with the guidelines. If certain groups 
(e.g., men, people in disadvantaged areas, non-smokers, and 
black people) may only come or be tested when they are in a 
more serious condition, those who were tested may be more 
likely to be positive for COVID-19. In contrast, groups with 
lower thresholds for presentation could be tested with less 
severe symptoms and therefore are more likely to be tested 
negative. Population surveys should provide consistent test 
levels by subgroups as far as possible to reduce the risk of se-
lection bias. Although RT-PCR testing is the gold standard 
for SARS-CoV-2 Diagnosis, the overall sensitivity of the test 
in the clinic, may be reduced by factors, such as smear tech-
nique and time relative to the onset of symptoms. Therefore, 
some SARS-CoV-2 cases could have been missed, especially 
among patients with lower viral loads.
Additional data are needed to establish the epidemiol-
ogy of SARS-CoV-2, especially with regard to emerging fac-
tors, such as ethnicity, deprivation, population density and 
smoking.
Conclusions
Primary health care network data provide important in-
formation on the epidemiology of SARS-CoV-2, although 
the study was limited by small sample and selection of pa-
tients who came for SARS-CoV-2 testing through routine 
health care services. It is necessary to continuously study the 
factors that influence the development of the epidemic, the 
severity of symptoms, and the conditions in which COVID 
infection spreads faster.
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